Stay updated on Gantenerumab in Mild Alzheimer Disease Clinical Trial
Sign up to get notified when there's something new on the Gantenerumab in Mild Alzheimer Disease Clinical Trial page.

Latest updates to the Gantenerumab in Mild Alzheimer Disease Clinical Trial page
- Check4 days agoChange DetectedThe ClinicalTrials.gov site revision label changed from v3.8.0 to v3.8.1, with no change to the study record content.SummaryDifference0.0%

- Check11 days agoChange DetectedThe completed Phase 3 study of gantenerumab for mild Alzheimer disease is now displayed, with its study design, eligibility criteria, outcomes, locations, and record documents.SummaryDifference100%

- Check18 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check32 days agoChange DetectedA site-wide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence.” The site revision label also changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check46 days agoChange DetectedThe site revision label changed from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page now displays a 403 Forbidden error screen with a minimal header and a Home link, replacing the full study record content that was previously visible. This indicates restricted access to the page.SummaryDifference18%

Stay in the know with updates to Gantenerumab in Mild Alzheimer Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Gantenerumab in Mild Alzheimer Disease Clinical Trial page.